ATOSSA THERAPEUTICS, INC.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
ATOS$2.14+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(amounts in thousands, except share data)
| Convertible Preferred Stock · Common Stock · Treasury Stock | ||||||||
|---|---|---|---|---|---|---|---|---|
| Additional · Total | ||||||||
| Shares | Amount | Shares | Amount | Paid-inCapital | Amount | AccumulatedDeficit | Stockholders'Equity | |
| Balance at December 31, 2022 | 582 | $— | 126,624,110 | $22,792 | $251,366 | $— | $(156,194) | $117,964 |
| Common stock repurchased | — | — | (1,320,046) | — | — | (1,475) | — | (1,475) |
| Stock-based compensation | — | — | — | — | 4,621 | — | — | 4,621 |
| Net loss | — | — | — | — | — | — | (30,094) | (30,094) |
| Balance at December 31, 2023 | 582 | $— | 125,304,064 | $22,792 | $255,987 | $(1,475) | $(186,288) | $91,016 |
| Issuance of common stock upon warrant exercise | — | — | 3,672,500 | 661 | 3,012 | — | — | 3,673 |
| Issuance of common stock upon option exercise | — | — | 343,998 | 62 | 211 | — | — | 273 |
| Shares withheld related to cashless exercise of options and taxes | — | — | (150,558) | (27) | (246) | — | — | (273) |
| Stock-based compensation | — | — | — | — | 2,292 | — | — | 2,292 |
| Net loss | — | — | — | — | — | — | (25,504) | (25,504) |
| Balance at December 31, 2024 | 582 | $— | 129,170,004 | $23,488 | $261,256 | $(1,475) | $(211,792) | $71,477 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.